sterna biologicals GmbH & Co. KG

sterna biologicals announces dosing of first patient in phase IIa proof-of-concept study with SB010 in moderate to severe asthma

sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS RECEIVES APPROVAL FOR INNOVATIVE PHASE II A STUDY DESIGN IN ASTHMA COMBINING A NOVEL ANTISENSE-BASED TREATMENT WITH A DIGITAL THERAPY

sterna biologicals GmbH & Co. KG raises further EUR 10.0 million (approx. USD 11.9 million) in Series A – 2nd closing private placement

Sterna biologicals secures EUR 12.0 million (approx. USD 13.0 million) in private placement

Sterna biologicals to attend international partnering and investor conferences in November

sterna biologicals invited to present at the Goodwin – Solebury Trout – NASDAQ European Biotech Investor Day 2019